Oncology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

MEDICAL FRONTIERS - 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)

A New Era Emerges In Melanoma Control, Including Brain Metastases

Chicago, Illinois / June 2-6, 2017

Chicago - A growing proportion of patients with advanced metastatic melanoma are surviving for long periods due largely to two approaches. One involves combining therapies targeted at the BRAF and MEK pathways. The other involves...

PRIORITY PRESS - Lung Cancer Summit 2015

The Right Drug at the Right Time in the Right Patient: Reflex Biomarker Testing in NSCLC Should Become a National Strategy

Toronto, Ontario / October 30, 2015

Toronto - Recent guidelines from the American Society of Clinical Oncologists state that systemic therapy for advanced non-squamous non-small cell lung cancer (NSCLC) should start with knowledge of a patient’s biomarker status...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the European Cancer Congress (ECC)

Neuroendocrine Tumours: Revised Strategies from New Trial Data

Vienna, Austria / September 25-29, 2015

Guest Editor: Simron Singh, MD, MPHStaff Oncologist Assistant Professor, University of TorontoSunnybrook Health Sciences Centre Toronto, Ontario   Introduction NET is a term for a genetically diverse group of solid tumours arising...

PRIORITY PRESS - 39th Annual Congress of the European Society for Medical Oncology (ESMO)

Survival Data Justify Early Use of Androgen Pathway Inhibitor in Metastatic Castration Resistant Prostate Cancer

Madrid, Spain / September 26-30, 2014

Madrid - The final overall survival (OS) results of a phase 3 multicentre trial have confirmed the value of first-line androgen inhibition in metastatic castration resistant prostate cancer (mCRPC). In the study, early use of an androgen...

PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)

Objective Response to a TKI in Metastatic Renal Cell Cancer Is Substantially Improved with Individualized Dose Schedules

Madrid, Spain / September 26-30, 2014

Madrid - Optimal response to a tyrosine kinase inhibitor (TKI) employed first line in metastatic renal cell carcinoma (mRCC) appears to be achieved by individualizing the dose and schedule in order to sustain dose intensity, according to...

PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)

Targeted Therapies Moving into First-Line Therapy Underscore Need for Baseline Molecular Testing of Lung Cancers

Madrid, Spain / September 26-30, 2014

Madrid - Guidelines issued by ESMO just prior to the annual Congress call for routine molecular testing at the time of diagnosis in all patients with non-small cell lung cancer (NSCLC). New phase 3 data on ALK-positive (ALK+) NSCLC...

PRIORITY PRESS - 2014 Genitourinary Cancers Symposium

Cardiovascular Risk with ADT for Advanced Prostate Cancer

San Francisco, California / January 30-February 1, 2014

San Francisco - The principal goal of androgen deprivation therapy (ADT) is to reduce testosterone to castrate levels, thereby depriving prostate cancer cells of their key growth substrate. However, several studies have shown that ADT...

PRIORITY PRESS - 55th Annual Meeting of the American Society of Hematology (ASH)

Strategies for Control of Multiple Myeloma Refined By New and Extended Data Analysis of Major Trials

New Orleans, Louisiana / December 7-10, 2013

New Orleans - Of data with practice-changing implications for control of multiple myeloma presented at ASH 2013, the most significant involved dosing of front-line therapy in those who are transplant-ineligible. In this group, it was shown...

PRIORITY PRESS - 36th Annual San Antonio Breast Cancer Symposium (SABCS)

Advances in Endocrine Therapy for Breast Cancer

San Antonio, Texas / December 10-14, 2013

San Antonio - Endocrine therapy is an important weapon in a clinician’s armamentarium against metastatic breast cancer (mBC). Several endocrine therapies are considered standard for hormone receptor-positive (HR+) postmenopausal...

PRIORITY PRESS - ECCO-17 - 38th ESMO Multidisciplinary Congress

Improving the Journey for Men with Metastatic Castrate Resistant Prostate Cancer

Amsterdam, The Netherlands / September 27-October 1, 2013

Amsterdam - Prostate cancer (PC) remains the most commonly diagnosed cancer in males and it is the second leading cause of death in men. Skeletal complication is the most important morbidity point in terms of metastases in PC and almost all...

PAGE 1 OF 20   1 2 3 4 5 6 7 8 9 10 ...